Alnylam Pharmaceuticals, Inc. vs Expeditors International of Wshngtn Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221 (market cap $29.60B), while Expeditors International of Wshngtn Inc trades at $177.4 (market cap $23.04B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EXPD | |
|---|---|---|
Market Cap | $29.60B | $23.04B |
Sector | Health | Industrials |
52-Week High | $491.22 | $182.80 |
52-Week Low | $205.48 | $113.13 |
Enterprise Value | $27.56B | $22.57B |
Dividend Yield | — | 0.91% |
Trailing returns across standard periods
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →